PATENT CLAIM ANALYSIS

Application Number: 16162459
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "256000"]

Abstract:
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , Y 1 , Y 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12  and R 13  are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Claim (Index 20):
The method of  claim 19  wherein the Mnk dependent condition is colorectal cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, pancreatic cancer, melanoma, multiple melanoma, brain cancer, CNS cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 97.0
- Lexical Diversity: 2.07576
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15337184', '14426369', '13420988', '13745734', '15355271']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7914483775261214
- 35 USC 102 Novelty (BERT): 0.5361352915882183
- Combined Prediction Score: 0.765917068932331
- Mean Citation Score: 324.329874
- Max Citation Score: 346.22852
- Similarity Product: 276.4030284462309

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test